- Home
- ANIX vs SRZN Comparison
ANIX vs SRZN Comparison
Compare ANIX & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- SRZN
- Stock Information
- Founded
- ANIX 1982
- SRZN 2015
- Country
- ANIX United States
- SRZN United States
- Employees
- ANIX N/A
- SRZN N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- ANIX Health Care
- SRZN Health Care
- Exchange
- ANIX Nasdaq
- SRZN Nasdaq
- Market Cap
- ANIX 95.7M
- SRZN 97.3M
- IPO Year
- ANIX 1987
- SRZN N/A
- Fundamental
- Price
- ANIX $3.35
- SRZN $11.55
- Analyst Decision
- ANIX Strong Buy
- SRZN Strong Buy
- Analyst Count
- ANIX 3
- SRZN 2
- Target Price
- ANIX $9.00
- SRZN $38.50
- AVG Volume (30 Days)
- ANIX 108.8K
- SRZN 12.2K
- Earning Date
- ANIX 09-10-2025
- SRZN 11-05-2025
- Dividend Yield
- ANIX N/A
- SRZN N/A
- EPS Growth
- ANIX N/A
- SRZN N/A
- EPS
- ANIX N/A
- SRZN N/A
- Revenue
- ANIX N/A
- SRZN $12,621,000.00
- Revenue This Year
- ANIX N/A
- SRZN N/A
- Revenue Next Year
- ANIX N/A
- SRZN N/A
- P/E Ratio
- ANIX N/A
- SRZN N/A
- Revenue Growth
- ANIX N/A
- SRZN N/A
- 52 Week Low
- ANIX $2.07
- SRZN $5.90
- 52 Week High
- ANIX $4.20
- SRZN $18.17
- Technical
- Relative Strength Index (RSI)
- ANIX 59.63
- SRZN 53.57
- Support Level
- ANIX $2.93
- SRZN $11.25
- Resistance Level
- ANIX $3.09
- SRZN $11.74
- Average True Range (ATR)
- ANIX 0.16
- SRZN 0.59
- MACD
- ANIX 0.06
- SRZN -0.13
- Stochastic Oscillator
- ANIX 62.69
- SRZN 21.37
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).